RCD – Rousaud Costas Duran has advised the biotech company Aelix Therapeutics on an €11.5M investment round; the money will be used to develop an effective vaccine against the HIV virus. Ysios Capital, a Spanish investment fund, led the round. The fundraising was also supported by Caixa Capital Risc and the American fund Johnson & Johnson Innovation.
Latest newsRCD news
RCD news


